VOR Vor Biopharma Inc.
USHealthcareAs of 2026-07-10 16:00
Why VOR matters now
Vor Biopharma Inc. (VOR) is a US stock in Healthcare. The latest InvestLog snapshot shows $19.14 with -3.09% on the session and $131.2M in market capitalization; recent performance reads 1-month +2.55% and YTD +10.78%.
The latest financial table shown here is Q1 2026, with revenue of $0.00, net income of $-219.6M, and EPS of $-510.53. Investors can compare that operating picture with valuation signals such as P/E unavailable and FCF yield -151.7%.
The latest indexable market news headline is "Vor Bio Appoints David Zaccardelli to Board of Directors" from GlobeNewsWire.
Additional event context on this page matters because analyst consensus is Buy with a median target of $31.00; recent insider activity includes Levin Andrew David filing A-Award. These signals are research inputs, not a recommendation.
Valuation
P/E (TTM)
—
PEG
—
P/B
-0.04
P/S
0.00
EV/EBITDA
-0.15
DCF Value
$39.40
FCF Yield
-151.7%
Div Yield
0.0%
Margins & Returns
Gross Margin
0.0%
Operating Margin
0.0%
Net Margin
0.0%
ROE
87.3%
ROA
-174.3%
ROIC
-76.1%
Financials
| Period | Revenue | Net Income | EPS |
|---|---|---|---|
| Q1 2026 | $0.00 | $-219.6M | $-510.53 |
| Q4 2025 | $0.00 | $1.72B | $44.50 |
| FY 2025 | $0.00 | $-696.0M | $-70.50 |
| Q3 2025 | $0.00 | $-812.7M | $-121.63 |
Analyst Ratings
Consensus
Buy
Target (Consensus)
$31.67
Target (Median)
$31.00
Target Range
$18.00 - $46.00
Trading Activity
Insider Trades
Related Stocks
Latest News
Company Info
Sector
Healthcare
Industry
Biotechnology
Country
US
Exchange
—
Beta
1.73
Vor Biopharma, Inc. is a clinical-stage biotechnology firm dedicated to developing innovative engineered hematopoietic stem cell (eHSC) therapies for individuals battling cancer. Its lead product candidate, VOR33, is an eHSC therapy currently undergoing Phase 1/2 clinical trials. VOR33 is designed to target acute myeloid leukemia (AML) and various other hematological malignancies. A key feature of VOR33's eHSCs is their engineered absence of the CD33 protein, which is commonly found on AML blood cancer cells. The company's eHSC platform is intended to enable a range of targeted blood cancer treatments, including CAR-T cell therapies, bispecific antibodies, and antibody-drug conjugates. Vor Biopharma has established a partnership with Akron BioProducts for the development and manufacturing of cGMP nucleases. Established in 2015, the company's headquarters are located in Cambridge, Massachusetts.